ABSTRACT
When we consider a probability distribution about how many COVID-19 infected people will transmit the disease, two points become important. First, there should be super-spreaders in these distributions/networks and secondly, the Pareto principle should be valid in these distributions/networks. When we accept that these two points are valid, the distribution of transmission becomes a discrete Pareto distribution, which is a kind of power law. Having such a transmission distribution, then we can simulate COVID-19 networks and find super-spreaders using the centricity measurements in these networks. In this research, in the first we transformed a transmission distribution of statistics and epidemiology into a transmission network of network science and secondly we try to determine who the super-spreaders are by using this network and eigenvalue centrality measure. We underline that determination of transmission probability distribution is a very important point in the analysis of the epidemic and determining the precautions to be taken.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research received no specific grant from any funding agency, commercial or not-for-profit sectors."
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was not required as the study was based on derived data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.